Application of a dermatopharmacokinetic (DPK) method for bioequivalence assessment of topical metronidazole creams

Authors

  • Seeprarani Rath Postdoctoral Fellow, Biopharmaceutics Research Institute, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa
  • Ashmita Ramanah Research Officer, Biopharmaceutics Research Institute, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa
  • Charles Bon Biostudy Solutions LLC., Wilmington, NC, USA
  • Isadore Kanfer Leslie Dan Faculty of Pharmacy University of Toronto Toronto, ON, M5S 3M2, Canada

DOI:

https://doi.org/10.18433/jpps31534

Abstract

Purpose: The main aim of the current research was to develop and apply a dermatopharmacokinetic (DPK) approach for the bioequivalence assessment of metronidazole (MTZ) topical cream products, indicated in the treatment of rosacea. Methods: A DPK methodology using tape stripping (TS) technique was developed by investigating the factors that may influence the TS results viz. tapes, dose durations, number of tapes to be used, pressure application, dose applied and gravimetric analysis of the tapes. An initial dose duration study was performed on 6 healthy participants to determine an appropriate application time duration using the Emax model. The SC thickness was normalised between participants using TEWL measurements. A pivotal study was conducted using both the arms of 10 healthy human participants to demonstrate the ability of the TS method for bioequivalence assessment by comparing the reference product to itself as a positive control and including products with higher and lower strengths of MTZ to serve as negative controls in order to confirm bioinequivalence. Results: Whereas the reference was found to be bioequivalent when compared to itself, the creams containing 0.56% and 0.95% MTZ (negative controls) were not bioequivalent (bioinequivalent). Furthermore, another product containing 0.75% MTZ was also assessed and was found to be bioequivalent to the reference product. In addition, the use of both forearms of each participant offered an important advantage of significantly reducing the number of human subjects required to demonstrate BE with a high statistical power of > 80%. Conclusion: The data obtained provides compelling evidence that the developed TS method has the potential to be a cost-effective surrogate alternative for lengthy and expensive clinical trials. Consequently, its application can facilitate faster development of generic products which would, in turn, lower the economic burden of healthcare.

Downloads

Download data is not yet available.

Author Biographies

Seeprarani Rath, Postdoctoral Fellow, Biopharmaceutics Research Institute, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa

Postdoctoral Fellow,

Biopharmaceutics Research Institute, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa

Charles Bon, Biostudy Solutions LLC., Wilmington, NC, USA

President,

Biostudy Solutions LLC., Wilmington, NC, USA

Isadore Kanfer, Leslie Dan Faculty of Pharmacy University of Toronto Toronto, ON, M5S 3M2, Canada

Professor,

Leslie Dan Faculty of Pharmacy

University of Toronto

Toronto, ON, M5S 3M2, Canada

Downloads

Published

2020-11-06

How to Cite

Rath, S., Ramanah, A., Bon, C., & Kanfer, I. (2020). Application of a dermatopharmacokinetic (DPK) method for bioequivalence assessment of topical metronidazole creams . Journal of Pharmacy & Pharmaceutical Sciences, 23, 437–450. https://doi.org/10.18433/jpps31534

Issue

Section

Pharmaceutical Sciences; Original Research Articles